PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1650993
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1650993
CAR T-cell Therapy
Global CAR T-cell Therapy Market to Reach US$10.8 Billion by 2030
The global market for CAR T-cell Therapy estimated at US$3.3 Billion in the year 2024, is expected to reach US$10.8 Billion by 2030, growing at a CAGR of 22.0% over the analysis period 2024-2030. DLBCL Indication, one of the segments analyzed in the report, is expected to record a 18.6% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the ALL Indication segment is estimated at 25.4% CAGR over the analysis period.
The U.S. Market is Estimated at US$944.0 Million While China is Forecast to Grow at 21.4% CAGR
The CAR T-cell Therapy market in the U.S. is estimated at US$944.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 21.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.8% and 18.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.1% CAGR.
Global CAR T-cell Therapy Market - Key Trends and Drivers Summarized
What Makes CAR T-Cell Therapy a Breakthrough in Cancer Treatment?
Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the landscape of cancer treatment, particularly for patients battling certain types of blood cancers that have not responded to conventional therapies like chemotherapy and radiation. This form of immunotherapy works by harnessing and enhancing the body's own immune system to target and destroy cancer cells. The process begins with the extraction of a patient’s T-cells, a type of white blood cell crucial to immune response. These T-cells are then genetically modified in a laboratory to express a receptor (CAR) that allows them to recognize specific proteins on the surface of cancer cells. Once the T-cells are modified and multiplied, they are reinfused into the patient’s body, where they seek out and destroy the cancer cells with extraordinary precision. CAR T-cell therapy has shown remarkable efficacy, particularly in treating hematologic cancers such as B-cell lymphomas and acute lymphoblastic leukemia (ALL). In many cases, patients who had exhausted all other treatment options have experienced long-term remission. This therapy represents a significant leap forward in personalized medicine, as it is tailored to the individual’s specific cancer profile, offering a customized approach that has been transformative in oncology.
How Are Technological Innovations Enhancing the Efficacy of CAR T-Cell Therapy?
The development of CAR T-cell therapy has been significantly advanced by cutting-edge technologies that have improved both the efficacy of the treatment and its safety profile. One of the most critical innovations has been the design of more sophisticated CAR constructs, allowing for greater precision in targeting cancer cells. Early iterations of CAR T-cell therapy targeted a single antigen on cancer cells, but newer versions are engineered to recognize multiple antigens, reducing the chances of the cancer evading detection. This has been especially important in addressing challenges like antigen escape, where cancer cells mutate to avoid immune destruction. In addition, advancements in gene-editing technologies, such as CRISPR, have enabled scientists to modify T-cells with increased accuracy, enhancing their ability to target cancer cells while reducing the risk of unintended effects on healthy tissues. Technological improvements in cell manufacturing processes have also reduced the time needed to modify and expand T-cells, making the therapy more accessible and reducing wait times for patients with aggressive cancers. Furthermore, the integration of artificial intelligence (AI) and machine learning into the development and administration of CAR T-cell therapy has enabled researchers and clinicians to predict patient responses more accurately, optimizing the treatment process. These innovations not only enhance the effectiveness of CAR T-cell therapy but also contribute to its scalability, ensuring that this powerful treatment is available to a broader range of patients worldwide.
What Are the Current Trends and Challenges in CAR T-Cell Therapy?
Several important trends are shaping the future of CAR T-cell therapy, reflecting both its promise and the challenges that must be addressed to maximize its potential. One of the most exciting trends is the expansion of CAR T-cell therapy beyond blood cancers to solid tumors. Historically, treating solid tumors has been more complex due to the protective environment these tumors create around themselves, making it difficult for immune cells to penetrate and attack. However, research is actively exploring ways to enhance T-cell infiltration into solid tumors and sustain their activity in the hostile tumor microenvironment. Another significant trend is the development of allogeneic, or "off-the-shelf," CAR T-cell therapies. Unlike the traditional approach that requires extracting and modifying a patient’s own cells (autologous therapy), allogeneic CAR T-cell therapy uses T-cells from healthy donors. This approach promises to significantly reduce the time and cost associated with the therapy, potentially making it more widely accessible. Despite these advancements, several challenges remain. Managing severe side effects, such as cytokine release syndrome (CRS) and neurotoxicity, remains a critical concern. These side effects occur when the immune system is over-activated by the therapy, causing inflammation and potentially dangerous complications. Research is focused on mitigating these risks, and several safety mechanisms, including built-in "suicide switches" that deactivate the CAR T-cells in emergencies, are being developed. Additionally, the high cost of manufacturing CAR T-cell therapy, often exceeding several hundred thousand dollars per patient, is a major barrier to broader adoption. This cost reflects the complexity of producing a personalized, living cell therapy, but efforts to streamline production and develop more efficient manufacturing techniques are underway to reduce costs.
What’s Driving Growth in the CAR T-Cell Therapy Market?
The growth in the CAR T-cell therapy market is driven by several factors, including technological advancements, expanding clinical indications, and the increasing demand for personalized cancer treatments. One of the primary drivers is the expanding body of clinical evidence demonstrating the efficacy of CAR T-cell therapy in treating various types of cancer, especially hematologic malignancies such as lymphoma, leukemia, and multiple myeloma. The potential for CAR T-cell therapy to move into the treatment of solid tumors represents another key growth opportunity, as ongoing research continues to investigate new therapeutic targets and applications in cancers like lung, breast, and pancreatic cancer. Technological improvements in gene-editing tools and cell manufacturing processes are also contributing to the market’s growth, allowing for faster and more cost-effective production of CAR T-cells. The increasing demand for personalized medicine is another crucial factor driving market expansion, as patients and healthcare providers look for treatments tailored to the unique genetic and molecular profile of individual cancers. This is especially important in cases where traditional therapies have failed, making CAR T-cell therapy a vital option for those with few alternatives. Additionally, the global rise in cancer prevalence is fueling demand for more innovative treatments, particularly in regions where regulatory approvals for CAR T-cell therapies are expanding, such as in Europe and Asia. The development of allogeneic CAR T-cell therapies, which could provide more affordable and widely available treatment options, further accelerates market growth. With continuous advancements in AI, which are improving treatment precision and monitoring, and the growing focus on enhancing patient outcomes, the CAR T-cell therapy market is positioned for robust growth in the years to come.
SCOPE OF STUDY:
The report analyzes the CAR T-cell Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Indication (DLBCL, ALL, MM, CLL, FL)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 12 Featured) -
- A2 Biotherapeutics, Inc.
- Adaptive Biotechnologies Corporation
- Advanced Cell & Gene Therapy
- AffyImmune Therapeutics
- Allogene Therapeutics
- Beam Therapeutics
- CARsgen Therapeutics
- Celgene Corporation
- Cellular Biomedicine Group, Inc.
- Innovacell
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- CAR T-cell Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Incidence of Cancer Throws the Spotlight on CAR T-Cell Therapy as a Key Treatment Option
- Technological Advancements in Gene Editing Propel Growth in CAR T-Cell Therapy Efficacy and Safety
- Expanding Clinical Applications Beyond Blood Cancers Expands Addressable Market Opportunity
- Here's How Personalized Medicine Strengthens the Business Case for CAR T-Cell Therapy
- Increased Research on Solid Tumor Applications Spurs Growth in CAR T-Cell Therapy Development
- Allogeneic 'Off-the-Shelf' CAR T-Cell Therapies Generate New Opportunities in Manufacturing
- Emerging Strategies to Combat Cytokine Release Syndrome Expands the Safety Profile of CAR T-Cell Therapy
- Global Focus on Precision Oncology Expands the Market for CAR T-Cell Therapies
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World CAR T-cell Therapy Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for CAR T-cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 3: World 6-Year Perspective for CAR T-cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for DLBCL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 5: World 6-Year Perspective for DLBCL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 6: World Recent Past, Current & Future Analysis for ALL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 7: World 6-Year Perspective for ALL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for MM by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 9: World 6-Year Perspective for MM by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 10: World Recent Past, Current & Future Analysis for CLL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 11: World 6-Year Perspective for CLL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 12: World Recent Past, Current & Future Analysis for FL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 13: World 6-Year Perspective for FL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 14: USA Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 15: USA 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
- CANADA
- TABLE 16: Canada Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 17: Canada 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
- JAPAN
- CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 18: Japan Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 19: Japan 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
- CHINA
- CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 20: China Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 21: China 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
- EUROPE
- CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 22: Europe Recent Past, Current & Future Analysis for CAR T-cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 23: Europe 6-Year Perspective for CAR T-cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
- TABLE 24: Europe Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 25: Europe 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
- FRANCE
- CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 26: France Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 27: France 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
- GERMANY
- CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 28: Germany Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 29: Germany 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
- ITALY
- TABLE 30: Italy Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 31: Italy 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
- UNITED KINGDOM
- CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 32: UK Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 33: UK 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
- REST OF EUROPE
- TABLE 34: Rest of Europe Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 35: Rest of Europe 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
- ASIA-PACIFIC
- CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 36: Asia-Pacific Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 37: Asia-Pacific 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
- REST OF WORLD
- TABLE 38: Rest of World Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 39: Rest of World 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
IV. COMPETITION
